文献速递其他结缔组织病

系统性硬化症患者多重用药、药物相互作用及药物不良反应:一项横断面危险因素研究

Polypharmacy, drug-drug interactions, and adverse drug reactions among systemic sclerosis patients: A cross-sectional risk factor study.
PubMed 文献 · Semin Arthritis Rheum · 2024-05-20

该研究回顾性分析2020年1月至2022年4月硬皮病门诊108例系统性硬化症患者的用药处方,发现66.7%存在药物相互作用,随访1年内6例(8.3%)发生药物不良反应;多因素分析显示处方药数量与药物相互作用(OR 2.25)及药物不良反应(OR 1.68)独立正相关。

要点

  • 108例系统性硬化症患者中位用药6种,65.7%使用5种及以上药物,21.3%使用10种及以上。
  • 66.7%患者处方存在药物相互作用,有相互作用者用药数多于无相互作用者(7 vs 3,p<0.0001)。
  • 随访1年内6例(8.3%)发生药物不良反应,有不良反应者用药数及相互作用数均更多。

核心结论

  • 系统性硬化症患者显著暴露于多重用药、药物相互作用及相关药物不良反应,尤其在重症病例及处方5种及以上药物时。

研究设计与样本

  • 回顾性分析2020年1月至2022年4月硬皮病日间门诊收治的系统性硬化症患者的药物处方,共纳入108例患者。
  • 使用2种处方分析应用识别药物相互作用,并报告随访1年期间发生的相关药物不良反应。
  • 采用多因素分析识别药物相互作用及药物不良反应的危险因素。

主要发现

  • 每例患者中位用药数为6种[4-9]。
  • 71例(65.7%)患者使用5种及以上药物,23例(21.3%)使用10种及以上。
  • 72例(66.7%)患者入组时处方存在药物相互作用;有相互作用者用药数多于无相互作用者(7[5-10] vs 3[2-5],p<0.0001)。
  • 随访1年内6例(8.3%)发生药物不良反应;有不良反应者用药数(14[10-18] vs 7[5-10],p<0.001)及药物相互作用数(12[7-32] vs 3[1-6],p<0.001)均多于无不良反应者。
  • 多因素分析证实处方药物数量与药物相互作用独立正相关(OR 2.25 [1.52-3.32],p<0.0001),也与药物不良反应独立正相关(OR 1.68 [1.17-2.40],p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence and determinants of DDI and ADR in a real-life prospective cohort of SSc patients. METHODS: We performed a retrospective analysis of the drug prescriptions of SSc patients admitted to the daily scleroderma clinic between January 2020 and April 2022. DDI were identified using 2 prescription analysis applications, and adjudicated related ADRs occurring during a one-year follow-up were reported. Risk factors for DDI and ADR were identified using multivariate analysis. RESULTS: One hundred and eight SSc patients were included. The median number of medications per patient was 6 [4-9]. Seventy-one (65.7 %) patients had 5 or more medications, and 23 (21.3 %) had 10 or more. Seventy-two (66.7 %) patients had DDIs on their prescriptions at inclusion. Patients with DDIs had more medications than patients without DDIs (7 [5-10] versus 3 [2-5], p < 0.0001). Six (8.3) patients experienced ADRs during the one-year follow-up. Patients with ADRs had more medications (14 [10-18] versus 7 [5-10] p < 0.001) and more DDIs (12 [7-32] versus 3 [1-6]; p < 0.001) than patients without ADRs. Multivariate analysis confirmed that the number of prescribed medications was independently positively associated with DDIs (OR: 2.25 [1.52-3.32], p < 0.0001) as well as with ADRs (OR: 1.68 [1.17-2.40], p < 0.01). CONCLUSIONS: SSc patients are significantly exposed to polypharmacy, DDIs and related ADRs, particularly in cases of severe illness, and especially if 5 or more medications are prescribed.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Boukhlal S, Chouchana L, Saadi M, et al. Polypharmacy, drug-drug interactions, and adverse drug reactions among systemic sclerosis patients: A cross-sectional risk factor study. Semin Arthritis Rheum. 2024. PMID: 38781783. doi:10.1016/j.semarthrit.2024.152469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。